InflaRx N.V. (IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, Wednesday said the European Medicines Agency or EMA has validated its Marketing Authorization Application or MAA for Vilobelimab to treat Critically Ill COVID-19 Patients.
from RTT - Before the Bell https://ift.tt/TXqWd3i
via IFTTT
No comments:
Post a Comment